The UCSF-GIVI CFAR Specimen Bank Core has since 1987 provided expertise and an infrastructure for the collection, processing and storage of biospecimens for CFAR investigators. The Specimen Bank Core, under the director of Dr. John S. Greenspan and Ms. Yvonne De Souza has provided repository services to many cohorts and clinical studies based in San Francisco, including the Women's Interagency HIV Study (WINS), Options Project (Primary HIV infection), Staying Well (Clinical trial of mindfulness-based stress reduction and education groups for HIV), SFGH Observational Cohort Evaluating Long-Term Consequences of Virologic Failure (SCOPE), and a recently funded NIH study, Men of Asia testing for HIV (MATH). The Specimen Bank Core has received over 295,000 deposits and has shipped over 275,000 specimens aliquots worldwide, including whole blood, serum, plasma, leukocytes, fresh frozen and fixed tissue, urine, saliva (stimulated and unstimulated), semen, cerebrospinal fluid, oral and vaginal mucosal swabs, and cervico-vaginal lavage. A goal of the Core is to continue its current repository functions and to further develop as a local and national source for investigators pursing translational research.
Specific Aims of the Specimen Bank Core (SBC) are to: 1. Process, inventory, and store (short and long term) biospecimens collected from CFAR investigators. 2. Provide well-characterized biospecimens to support CFAR investigations and to provide specimens to non-CFAR investigators to enhance collaboration between CFAR and non-CFAR investigators. 3. Provide consultation and training for CFAR investigators seeking information on optimal specimen collection, processing, storage, and shipment. 4. Advise the International Core in specimen banking and storage procedures.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027763-20
Application #
8331625
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
20
Fiscal Year
2011
Total Cost
$217,825
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Yukl, Steven A; Kaiser, Philipp; Kim, Peggy et al. (2018) HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci Transl Med 10:
Roy, Monika; Holmes, Charles; Sikazwe, Izukanji et al. (2018) Application of a Multistate Model to Evaluate Visit Burden and Patient Stability to Improve Sustainability of Human Immunodeficiency Virus Treatment in Zambia. Clin Infect Dis 67:1269-1277
Kiniry, Brenna E; Hunt, Peter W; Hecht, Frederick M et al. (2018) Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 Infection. J Immunol 200:1876-1888
Jeng, Mark Y; Hull, Philip A; Fei, Mingjian et al. (2018) Metabolic reprogramming of human CD8+ memory T cells through loss of SIRT1. J Exp Med 215:51-62
Chitre, Avantika S; Kattah, Michael G; Rosli, Yenny Y et al. (2018) A20 upregulation during treated HIV disease is associated with intestinal epithelial cell recovery and function. PLoS Pathog 14:e1006806
Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:
Prakash, Katya; Gianella, Sara; Dubé, Karine et al. (2018) Willingness to participate in HIV research at the end of life (EOL). PLoS One 13:e0199670
Leonard, Brandon; Brand, Toni M; O'Keefe, Rachel A et al. (2018) BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC. Cancer Res 78:4331-4343
Wang, Chia-Ching; Thanh, Cassandra; Gibson, Erica A et al. (2018) Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. Blood Adv 2:3479-3482
Castillo-Mancilla, Jose R; Morrow, Mary; Boum, Yap et al. (2018) Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic Suppression. J Acquir Immune Defic Syndr 77:507-513

Showing the most recent 10 out of 1541 publications